Both in Pharmaceuticals
Spero Therapeutics vs RenovoRx
Over the past year SPRO returned −56.3% and RNXT returned +18.3%; their daily moves had a correlation of 0.18.
SPRO −56.3% RNXT +18.3%Growth of $1, one year, split-adjusted
| Metric | SPRO | RNXT |
|---|---|---|
| Price | $1.04 | $1.29 |
| Market cap | $60.6M | $58.2M |
| Today | 0.00% | +2.38% |
| 1 month | −10.3% | −12.2% |
| 6 months | −57.0% | +39.0% |
| Year to date | −55.4% | +53.6% |
| 1 year | −57.2% | +16.2% |
| Revenue growth (YoY) | −100.0% | +115.4% |
| Gross margin | — | 84.3% |
| Net margin | — | −320.2% |
| P/E (TTM) | 8.2× | — |
| Price / sales | 1.3× | 29.5× |
| Net cash | $50.7M | $9.5M |
| Dividend yield | — | — |
| Volatility (60d) | 58.7% | 108.4% |
| Short % of float | 2.0% | 2.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).